Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models

Mark J. Canet, Rhiannon N. Hardwick, April D. Lake, Anika L. Dzierlenga, John D. Clarke, Nathan J Cherrington

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Nonalcoholic fatty liver disease is a prevalent form of chronic liver disease that can progress to the more advanced stage of nonalcoholic steatohepatitis (NASH). NASH has been shown to alter drug transporter regulation and may have implications in the development of adverse drug reactions. Several experimental rodent models have been proposed for the study of NASH, but no single model fully recapitulates all aspects of the human disease. The purpose of the current study was to determine which experimental NASH model best reflects the known alterations in human drug transporter expression to enable more accurate drug disposition predictions in NASH. Both rat and mouse NASH models were used in this investigation and include the methionine and choline deficient (MCD) diet model, atherogenic diet model, ob/ob and db/db mice, and fa/fa rats. Pathologic scoring evaluations demonstrated that MCD and atherogenic rats, as well as ob/ob and db/db mice, developed NASH. Liver mRNA and protein expression analyses of drug transporters showed that in general, efflux transporters were induced and uptake transporters were repressed in the rat MCD and the mouse ob/ob and db/db models. Lastly, concordance analyses suggest that both the mouse and rat MCD models as well as mouse ob/ob and db/db NASH models show the most similarity to human transporter mRNA and protein expression. These results suggest that the MCD rat and mouse model, as well as the ob/ob and db/db mouse models, may be useful for predicting altered disposition of drugs with similar kinetics across humans and rodents.

Original languageEnglish (US)
Pages (from-to)586-595
Number of pages10
JournalDrug Metabolism and Disposition
Volume42
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Rodentia
Theoretical Models
Choline
Methionine
Pharmaceutical Preparations
Atherogenic Diet
Non-alcoholic Fatty Liver Disease
Messenger RNA
Drug and Narcotic Control
Drug-Related Side Effects and Adverse Reactions
Liver Diseases
Proteins
Chronic Disease
Diet
Liver

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models. / Canet, Mark J.; Hardwick, Rhiannon N.; Lake, April D.; Dzierlenga, Anika L.; Clarke, John D.; Cherrington, Nathan J.

In: Drug Metabolism and Disposition, Vol. 42, No. 4, 2014, p. 586-595.

Research output: Contribution to journalArticle

Canet, Mark J. ; Hardwick, Rhiannon N. ; Lake, April D. ; Dzierlenga, Anika L. ; Clarke, John D. ; Cherrington, Nathan J. / Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models. In: Drug Metabolism and Disposition. 2014 ; Vol. 42, No. 4. pp. 586-595.
@article{214ca92516cb4499ad75d1bded7c6b54,
title = "Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models",
abstract = "Nonalcoholic fatty liver disease is a prevalent form of chronic liver disease that can progress to the more advanced stage of nonalcoholic steatohepatitis (NASH). NASH has been shown to alter drug transporter regulation and may have implications in the development of adverse drug reactions. Several experimental rodent models have been proposed for the study of NASH, but no single model fully recapitulates all aspects of the human disease. The purpose of the current study was to determine which experimental NASH model best reflects the known alterations in human drug transporter expression to enable more accurate drug disposition predictions in NASH. Both rat and mouse NASH models were used in this investigation and include the methionine and choline deficient (MCD) diet model, atherogenic diet model, ob/ob and db/db mice, and fa/fa rats. Pathologic scoring evaluations demonstrated that MCD and atherogenic rats, as well as ob/ob and db/db mice, developed NASH. Liver mRNA and protein expression analyses of drug transporters showed that in general, efflux transporters were induced and uptake transporters were repressed in the rat MCD and the mouse ob/ob and db/db models. Lastly, concordance analyses suggest that both the mouse and rat MCD models as well as mouse ob/ob and db/db NASH models show the most similarity to human transporter mRNA and protein expression. These results suggest that the MCD rat and mouse model, as well as the ob/ob and db/db mouse models, may be useful for predicting altered disposition of drugs with similar kinetics across humans and rodents.",
author = "Canet, {Mark J.} and Hardwick, {Rhiannon N.} and Lake, {April D.} and Dzierlenga, {Anika L.} and Clarke, {John D.} and Cherrington, {Nathan J}",
year = "2014",
doi = "10.1124/dmd.113.055996",
language = "English (US)",
volume = "42",
pages = "586--595",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

TY - JOUR

T1 - Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models

AU - Canet, Mark J.

AU - Hardwick, Rhiannon N.

AU - Lake, April D.

AU - Dzierlenga, Anika L.

AU - Clarke, John D.

AU - Cherrington, Nathan J

PY - 2014

Y1 - 2014

N2 - Nonalcoholic fatty liver disease is a prevalent form of chronic liver disease that can progress to the more advanced stage of nonalcoholic steatohepatitis (NASH). NASH has been shown to alter drug transporter regulation and may have implications in the development of adverse drug reactions. Several experimental rodent models have been proposed for the study of NASH, but no single model fully recapitulates all aspects of the human disease. The purpose of the current study was to determine which experimental NASH model best reflects the known alterations in human drug transporter expression to enable more accurate drug disposition predictions in NASH. Both rat and mouse NASH models were used in this investigation and include the methionine and choline deficient (MCD) diet model, atherogenic diet model, ob/ob and db/db mice, and fa/fa rats. Pathologic scoring evaluations demonstrated that MCD and atherogenic rats, as well as ob/ob and db/db mice, developed NASH. Liver mRNA and protein expression analyses of drug transporters showed that in general, efflux transporters were induced and uptake transporters were repressed in the rat MCD and the mouse ob/ob and db/db models. Lastly, concordance analyses suggest that both the mouse and rat MCD models as well as mouse ob/ob and db/db NASH models show the most similarity to human transporter mRNA and protein expression. These results suggest that the MCD rat and mouse model, as well as the ob/ob and db/db mouse models, may be useful for predicting altered disposition of drugs with similar kinetics across humans and rodents.

AB - Nonalcoholic fatty liver disease is a prevalent form of chronic liver disease that can progress to the more advanced stage of nonalcoholic steatohepatitis (NASH). NASH has been shown to alter drug transporter regulation and may have implications in the development of adverse drug reactions. Several experimental rodent models have been proposed for the study of NASH, but no single model fully recapitulates all aspects of the human disease. The purpose of the current study was to determine which experimental NASH model best reflects the known alterations in human drug transporter expression to enable more accurate drug disposition predictions in NASH. Both rat and mouse NASH models were used in this investigation and include the methionine and choline deficient (MCD) diet model, atherogenic diet model, ob/ob and db/db mice, and fa/fa rats. Pathologic scoring evaluations demonstrated that MCD and atherogenic rats, as well as ob/ob and db/db mice, developed NASH. Liver mRNA and protein expression analyses of drug transporters showed that in general, efflux transporters were induced and uptake transporters were repressed in the rat MCD and the mouse ob/ob and db/db models. Lastly, concordance analyses suggest that both the mouse and rat MCD models as well as mouse ob/ob and db/db NASH models show the most similarity to human transporter mRNA and protein expression. These results suggest that the MCD rat and mouse model, as well as the ob/ob and db/db mouse models, may be useful for predicting altered disposition of drugs with similar kinetics across humans and rodents.

UR - http://www.scopus.com/inward/record.url?scp=84896123415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896123415&partnerID=8YFLogxK

U2 - 10.1124/dmd.113.055996

DO - 10.1124/dmd.113.055996

M3 - Article

C2 - 24384915

AN - SCOPUS:84896123415

VL - 42

SP - 586

EP - 595

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 4

ER -